NO894465L - Preparat med oekt penetrasjon gjennom huden. - Google Patents

Preparat med oekt penetrasjon gjennom huden.

Info

Publication number: NO894465L
Authority: NO; Norway
Prior art keywords: skin; prepared; carbon atoms; penetration; real penetration
Prior art date: 1988-11-11

Application number

NO89894465A

Other languages

English (en)

Other versions

NO176082C (no

NO176082B (no

NO894465D0 (no

Inventor

Mitsuhiro Yoshida

Hiroyuki Fujimori

Hidenori Asakawa

Masayoshi Kasai

Masanori Kayano

Shigemitsu Osawa

Original Assignee

Eisai Co Ltd

Sansho Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-11-11

Filing date

1989-11-09

Publication date

1990-05-14

1989-11-09 Application filed by Eisai Co Ltd, Sansho Co filed Critical Eisai Co Ltd

1989-11-09 Publication of NO894465D0 publication Critical patent/NO894465D0/no

1990-05-14 Publication of NO894465L publication Critical patent/NO894465L/no

1994-10-24 Publication of NO176082B publication Critical patent/NO176082B/no

1995-02-01 Publication of NO176082C publication Critical patent/NO176082C/no

Links

230000035515 penetration Effects 0.000 title 1
125000004432 carbon atom Chemical group C* 0.000 abstract 2
DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 abstract 1
LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 abstract 1
RHLJLALHBZGAFM-UHFFFAOYSA-N Bunazosinum Chemical compound C1CN(C(=O)CCC)CCCN1C1=NC(N)=C(C=C(OC)C(OC)=C2)C2=N1 RHLJLALHBZGAFM-UHFFFAOYSA-N 0.000 abstract 1
229960002467 bunazosin Drugs 0.000 abstract 1
235000014113 dietary fatty acids Nutrition 0.000 abstract 1
229930195729 fatty acid Natural products 0.000 abstract 1
239000000194 fatty acid Substances 0.000 abstract 1
150000004665 fatty acids Chemical class 0.000 abstract 1
150000003903 lactic acid esters Chemical class 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Oil, Petroleum & Natural Gas (AREA)
Dermatology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Cardiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

NO894465A 1988-11-11 1989-11-09 Fremgangsmåte for fremstilling av et farmasöytisk preparat inneholdende bunazosin, for perkutan tilförsel NO176082C (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP63285428A JP2794022B2 (ja)	1988-11-11	1988-11-11	ブナゾシン或いはその塩類含有経皮適用製剤

Publications (4)

Publication Number	Publication Date
NO894465D0 NO894465D0 (no)	1989-11-09
NO894465L true NO894465L (no)	1990-05-14
NO176082B NO176082B (no)	1994-10-24
NO176082C NO176082C (no)	1995-02-01

Family

ID=17691396

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO894465A NO176082C (no)	1988-11-11	1989-11-09	Fremgangsmåte for fremstilling av et farmasöytisk preparat inneholdende bunazosin, for perkutan tilförsel

Country Status (11)

Country	Link
US (1)	US5041437A (no)
EP (1)	EP0368339B1 (no)
JP (1)	JP2794022B2 (no)
AT (1)	ATE90873T1 (no)
AU (1)	AU615115B2 (no)
CA (1)	CA2001574A1 (no)
DE (1)	DE68907312T2 (no)
DK (1)	DK559989A (no)
ES (1)	ES2057064T3 (no)
FI (1)	FI92149C (no)
NO (1)	NO176082C (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH06509099A (ja) *	1991-07-03	1994-10-13	サノ・コーポレーシヨン	ジクロフエナツクの経皮デリバリーに対する組成物及び方法
US5900250A (en) *	1992-05-13	1999-05-04	Alza Corporation	Monoglyceride/lactate ester permeation enhancer for oxybutnin
NZ274711A (en) *	1993-09-29	1996-11-26	Alza Corp	Composition for administration of active agent by application to a body surface or membrane comprising permeability enhancing amount of monoglyceride(s) and lactate ester(s)
US5420106A (en) *	1994-03-22	1995-05-30	Bristol-Myers Squibb Company	Method and composition having enhanced alpha-hydroxy acid skin permeation and retention
US5503843A (en) *	1994-04-22	1996-04-02	Flora Inc.	Transdermal delivery of alpha adrenoceptor blocking agents
GB2301878A (en) *	1995-06-06	1996-12-18	Hardware & Systems Patents Ltd	Ventilator:mounting
EP1152749B1 (en) †	1999-02-08	2006-04-12	ALZA Corporation	Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US7258869B1 (en)	1999-02-08	2007-08-21	Alza Corporation	Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US7179483B2 (en)	2000-04-26	2007-02-20	Watson Pharmaceuticals, Inc.	Compositions and methods for transdermal oxybutynin therapy
US7731947B2 (en)	2003-11-17	2010-06-08	Intarcia Therapeutics, Inc.	Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US11246913B2 (en)	2005-02-03	2022-02-15	Intarcia Therapeutics, Inc.	Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en)	2005-02-03	2006-08-10	Alza Corporation	Solvent/polymer solutions as suspension vehicles
EP2020990B1 (en)	2006-05-30	2010-09-22	Intarcia Therapeutics, Inc	Two-piece, internal-channel osmotic delivery system flow modulator
PL2359808T3 (pl)	2006-08-09	2013-10-31	Intarcia Therapeutics Inc	Osmotyczne systemy dostawcze i zespoły tłokowe
EP2157967B1 (en)	2007-04-23	2013-01-16	Intarcia Therapeutics, Inc	Suspension formulations of insulinotropic peptides and uses thereof
EP2240155B1 (en)	2008-02-13	2012-06-06	Intarcia Therapeutics, Inc	Devices, formulations, and methods for delivery of multiple beneficial agents
EP3323423B1 (en)	2009-09-28	2020-06-17	Intarcia Therapeutics, Inc	Rapid establishment and/or termination of substantial steady-state drug delivery
US20120208755A1 (en)	2011-02-16	2012-08-16	Intarcia Therapeutics, Inc.	Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US9889085B1 (en)	2014-09-30	2018-02-13	Intarcia Therapeutics, Inc.	Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
ES2968262T3 (es)	2015-06-03	2024-05-08	I2O Therapeutics Inc	Sistemas de colocación de implantes
KR20240037175A (ko)	2016-05-16	2024-03-21	인타르시아 세라퓨틱스 인코포레이티드	글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD860451S1 (en)	2016-06-02	2019-09-17	Intarcia Therapeutics, Inc.	Implant removal tool
USD840030S1 (en)	2016-06-02	2019-02-05	Intarcia Therapeutics, Inc.	Implant placement guide
AU2018206539A1 (en)	2017-01-03	2019-07-18	Intarcia Therapeutics, Inc.	Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4377581A (en) *	1980-03-03	1983-03-22	Pfizer Inc.	Chloro- and alkoxy-substituted-2,4-diaminoquinazolines
JPS58225009A (ja) *	1982-06-23	1983-12-27	Shionogi & Co Ltd	コルチコステロイド外用製剤
JPS6122512A (ja) *	1984-07-06	1986-01-31	ヤマハ株式会社	ワイヤハ−ネス製造システム用コネクタ−配置ヘッド
JPS6169721A (ja) *	1984-09-13	1986-04-10	Kao Corp	抗真菌組成物
US4925837A (en) *	1984-09-14	1990-05-15	Synthelabo	Pharmaceutical compositions
JPS61225122A (ja) *	1985-03-30	1986-10-06	Eisai Co Ltd	キナツオリン系化合物含有組成物
JPH0735332B2 (ja) *	1986-02-25	1995-04-19	久光製薬株式会社	外用クリ−ム製剤
JP2521091B2 (ja) *	1986-06-18	1996-07-31	日研化学株式会社	カテコ−ルアミン類の外用製剤
JPH0816066B2 (ja) *	1986-07-18	1996-02-21	エーザイ株式会社	持続性薬効製剤
US4766842A (en) *	1987-04-29	1988-08-30	Jon Long	Method and means for wave soldering of leads of an integrated circuit package

1988
- 1988-11-11 JP JP63285428A patent/JP2794022B2/ja not_active Expired - Fee Related
1989
- 1989-10-24 FI FI895045A patent/FI92149C/fi not_active IP Right Cessation
- 1989-10-26 CA CA002001574A patent/CA2001574A1/en not_active Abandoned
- 1989-10-27 AU AU43845/89A patent/AU615115B2/en not_active Ceased
- 1989-10-27 US US07/428,240 patent/US5041437A/en not_active Expired - Fee Related
- 1989-11-09 DK DK559989A patent/DK559989A/da not_active Application Discontinuation
- 1989-11-09 NO NO894465A patent/NO176082C/no unknown
- 1989-11-10 EP EP89120888A patent/EP0368339B1/en not_active Expired - Lifetime
- 1989-11-10 DE DE89120888T patent/DE68907312T2/de not_active Expired - Fee Related
- 1989-11-10 ES ES89120888T patent/ES2057064T3/es not_active Expired - Lifetime
- 1989-11-10 AT AT89120888T patent/ATE90873T1/de not_active IP Right Cessation

Also Published As

Publication number	Publication date
FI895045A0 (fi)	1989-10-24
ES2057064T3 (es)	1994-10-16
AU4384589A (en)	1990-05-17
FI92149C (fi)	1994-10-10
EP0368339B1 (en)	1993-06-23
DK559989D0 (da)	1989-11-09
ATE90873T1 (de)	1993-07-15
NO176082C (no)	1995-02-01
DE68907312T2 (de)	1993-11-25
CA2001574A1 (en)	1990-05-11
DE68907312D1 (de)	1993-07-29
AU615115B2 (en)	1991-09-19
DK559989A (da)	1990-05-12
EP0368339A2 (en)	1990-05-16
JP2794022B2 (ja)	1998-09-03
FI92149B (fi)	1994-06-30
NO176082B (no)	1994-10-24
JPH02131426A (ja)	1990-05-21
EP0368339A3 (en)	1990-12-19
US5041437A (en)	1991-08-20
NO894465D0 (no)	1989-11-09

Publication	Publication Date	Title
NO894465D0 (no)	1989-11-09	Preparat med oekt penetrasjon gjennom huden.
DE69311278D1 (de)	1997-07-10	Stabile pharmazeutische Zubereitung mit Fumagillolderivaten
HUT56290A (en)	1991-08-28	Plaster of oestrogenic active ingredient content and method for producing same
JPS6452716A (en)	1989-02-28	Endermically applicable preparation containing eperisone, tolperisone or salt thereof
ATE96678T1 (de)	1993-11-15	Verfahren zur verminderung von hautirritationen bei anwendung von durchdringungsverstaerkenden arzneimittelzusammensetzungen.
DE3772139D1 (de)	1991-09-19	Kosmetische zusammensetzung.
SE8803141D0 (sv)	1988-09-07	Neringsmedel for menniskor och djur
ES2123177T3 (es)	1999-01-01	Preparacion de absorcion percutanea que contiene buprenorfina.
GB8524421D0 (en)	1985-11-06	Therapeutic agents
BR9401199A (pt)	1994-10-18	Preparados de medicamentos, processo para a preparação de um preparado de medicamento, processo para a preparação de uma formulação de medicamento.
KR940005267A (ko)	1994-03-21	경피투여용 기제
ATE206914T1 (de)	2001-11-15	Verwendung von ursolsäure zur herstellung eines arzneimittels zur unterdrückung von metastasen
NO932236L (no)	1993-06-17	Farmasoeytisk preparat inneholdende probukol med forhoeyet biotilgjengelighet
BE1002024A6 (fr)	1990-05-22	Preparation medicamenteuse a base de derives d'esters d'hecogenine et leur utilisation pour le traitement de l'hyperplasie prostatique benigne.
IE772666L (en)	1978-06-30	Pharmaceutical composition
JPS5791913A (en)	1982-06-08	Pharmaceutical preparation of drug
SE8600496L (sv)	1986-08-06	Farmaceutiska kompositioner innehallande 9,10-dihydroergotalkaloider
DE3862440D1 (de)	1991-05-23	Pharmazeutische oder kosmetische zusammensetzung mit gehalt an hydrochinon und kojisaeure in liposomen.
IL82639A0 (en)	1987-11-30	Transdermal pharmaceutical composition
IT1214658B (it)	1990-01-18	Esteri polisaccaridici e loro sali
GB2208798B (en)	1991-06-05	Anti-cancer agent comprising l-ascorbic acid and o-benzylidene-l-ascorbic acid or deuterated derivative
JPS5659714A (en)	1981-05-23	Improver and remedy for dysbulia or depression
JPS5640607A (en)	1981-04-16	Drug composition
IT1203815B (it)	1989-02-23	Esteri polisaccaridici e loro sali
SE9002067D0 (sv)	1990-06-08	The pharmacological use of certain cystine derivatives